In this study, a high expression of MMS22L resulted in resistance to 2-hydroxyflutamide, suggesting that targeting MMS22L may be a strategy to improve the current androgen-targeted suppression of HCC. This evidence concerns the gene MMS22L and hepatocellular carcinoma.